Hefei Lifeon Pharmaceutical Co., Ltd.

Hefei Lifeon Pharmaceutical Co., Ltd. is a pharmaceutical company founded in 2002 and listed on the Shenzhen Stock Exchange in 2020. The company specializes in the research, development, production, and sales of pharmaceutical products and active pharmaceutical ingredients (APIs). Its product portfolio includes a variety of therapeutic areas such as cardiovascular, gastrointestinal, dermatological, ophthalmology, and central nervous system (CNS) products. Hefei Lifeon has established a strong position in the pharmaceutical industry, particularly in osmotic pump controlled-release technology. The company operates primarily in two business segments: pharmaceutical production and pharmaceutical commerce. It has developed a comprehensive osmotic pump technology platform, which underpins its competitive advantage in sustained and controlled release formulations. Hefei Lifeon also engages in wholesale distribution and retailing of pharmaceuticals and medical devices, with a notable presence in Anhui Province. In 2023, the company partially divested its pharmaceutical wholesale distribution business, transferring control of its subsidiary Anhui Lifeon Pharmaceuticals to China Resources Glory Health Technology. This strategic move allows Hefei Lifeon to focus on enhancing its capabilities in the pharmaceutical sector.

The company's highlights lie in its leading advantage in the field of osmotic pump technology within the domestic pharmaceutical industry. It has consistently focused on research and development in various aspects of osmotic pump technology, including formulation, formulation evaluation, formulation engineering, and critical equipment technology. Through technical research and development on crucial elements of osmotic pump formulations, the company has achieved technological breakthroughs, mastered various critical osmotic pump technologies, and gradually established the osmotic pump technology platform. By leveraging this technical advantage, the company has gained a competitive edge in the market and steadily proved its core competitiveness of sustained/controlled release preparation industrialization. The core technology, "Research and Industrial Application of Osmotic Pump Controlled-Release Technology for Poorly Soluble Drugs with Single-Layer Core," was awarded the first prize in the 2018 Anhui Science and Technology Awards. The company has continuously enhanced its capabilities in sustained/controlled-release formulation development and industrialization, strengthened the production and profitability of existing sustained/controlled-release products and built a rich pipeline of sustained/controlled-release products. Currently, the company has launched several sustained/controlled-release products in the market, including Felodipine Extended-Release Tablets, Doxazosin Mesylate Extended-release Tablets, Nifedipine Controlled-Release Tablets, Trimetazidine Hydrochloride Modified-release Tablets, Venlafaxine Hydrochloride Sustained-Release Tablets and Oxycodone Hydrochloride Prolonged -Release Tablets. Additionally, several sustained/controlled release formulations are in various stages of development, such as bioequivalence studies, pilot-scale production, and pharmaceutical research. The company is actively expanding its presence in the central nervous system drugs market, which includes medications for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases that affect the central nervous system. The company has obtained designated production licenses for anaesthetic drugs(Oxycodone Hydrochloride Prolonged-Release Tablets). Both Venlafaxine Hydrochloride Extended-Release Tablets and Oxycodone Hydrochloride Prolonged-Release Tablets have been approved for marketing. Large-size (40mg) Oxycodone Hydrochloride Prolonged-Release Tablets have been registered. Methylphenidate Hydrochloride Sustained-Release Tablets are bioequivalence studies, and several other central nervous system drugs are currently in the research and development stage. This strategic move aims to create new core competencies for the company. The company also offers a range of distinctive products, including Yiqi Hewei Capsules, Kunning Granules, Armillariella Oral Solution, Paeonol Ointment, Kecuoyintong Gel, and Jinzhen Eye Drops, covering various fields such as digestion, dermatology, gynaecology, and ophthalmology. The ophthalmology and dermatology products have pharmaceutical and consumer attributes, showing strong market potential and performing well at the retail level. Additionally, the company has independently developed and produced some active pharmaceutical ingredients, excipients, and pharmaceutical intermediates. The formulation products like Felodipine Extended-Release Tablets, Urea Vitamin E Cream, Paeonol Ointment, and Doxazosin Mesylate Extended-Release Tablets enable the company to achieve self-sufficiency in critical raw materials and excipients, ensuring cost advantages during centralized procurement.